noe-105
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 25, 2022 (NCT05583955)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 10AINHIBITOR
PDE10A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1ncc(C(=O)N2CCOCC2)c1C(=O)Nc1ccn2nc(-c3ccccc3)nc2c1- Mol. weight
- 431.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314465 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06315751 | Phase 2 | Sep 10, 2024 | Noema Pharma AG |
| NCT05583955 | Phase 2 | Jul 25, 2022 | Noema Pharma AG |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Noema Pharma AG | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1